Change of Adviser

RNS Number : 6958K

e-Therapeutics plc

27 June 2014

 



e-Therapeutics plc

Appointment of Nominated Adviser and Corporate Broker

Oxford and Newcastle, UK, 27 June 2014 - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, has appointed N+1 Singer Advisory LLP ("N+1 Singer") as its Nominated Adviser and Broker with immediate effect.

- Ends -

Contacts:

e-Therapeutics plc

Steve Medlicott, Finance Director

Tel: [phone]

www.etherapeutics.co.uk  

N+1 Singer

Aubrey Powell / Jen Boorer

Tel: [phone]

www.n1singer.com 

Instinctif Partners

Melanie Toyne-Sewell / Emma Barlow

Tel: [phone]

Email: [e-mail]

About e-Therapeutics plc

e-Therapeutics is an AIM-quoted drug discovery and development company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is currently focused in cancer and disorders of the nervous system.

e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.

 

END

 

 

APPBQLLLZQFBBBL